The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Abstract
Key Points: IDH1 promotes leukemogenesis in vivo in cooperation with HoxA9. Pharmacologic inhibition of mutant IDH1 efficiently inhibits AML cells of IDH1-mutated patients but not of normal CD34+ bone marrow cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in vivo transplantation experiments have shown that the overexpression of HOXA9 dysregulates MAPK signalling and collaborates with IDH1R132H to induce a short-latency AML in mice.9”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [9]
In the citing paper
“The homeobox protein HOXA9 contributes to haematopoiesis and is frequently overexpressed in human AMLs,8 notably in patients harbouring the IDH1R132H mutation.9”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [9]
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Setsukinai, K.-I., Urano, Y., Kakinuma, K., Majima, H. J., & Nagano, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209264200 · Cited by 1,301
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Käyser, S., Zucknick, M., Götze, K. S. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 820
Marcucci, G., Maharry, K. S., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 785
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Cairns, R. A., Iqbal, J., Lemonnier, F., Küçük, C., de Leval, L., Jaïs, J., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391748 · Cited by 522
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
Kogan, S. C., Ward, J. M., Anver, M. R., Berman, J. J., Brayton, C., Cardiff, R. D., Carter, J. S., de Coronado, S., Downing, J. R., Fredrickson, T. N., et al. (2002) · Blood · doi:10.1182/blood.v100.1.238 · Cited by 418
Abbas, S., Lugthart, S., Kavelaars, F. G., Schelen, A. M., Koenders, J. E., Zeilemaker, A., van Putten, W. J. L., Rijneveld, A. W., Löwenberg, B., & Valk, P. J. M. (2010) · Blood · doi:10.1182/blood-2009-11-250878 · Cited by 400
Sallmyr, A., Fan, J., Datta, K., Kim, K.-T., Grosu, D., Shapiro, P. S., Small, D., & Rassool, F. V. (2008) · Blood · doi:10.1182/blood-2007-05-092510 · Cited by 330
Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
Green, A. R., & Beer, P. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 295
Wagner, K., Damm, F., Göhring, G., Görlich, K., Heuser, M., Schäfer, I., Ottmann, O. G., Lübbert, M., Heit, W. F. W., Kanz, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6899 · Cited by 248
Self-citationHeuser, M., Beutel, G., Krauter, J., Döhner, K., Neuhoff, N. V., Schlegelberger, B., & Ganser, A. (2006) · Blood · doi:10.1182/blood-2006-04-014845 · Cited by 232
Self-citationChou, W., Hou, H., Chen, C., Tang, J., Yao, M., Tsay, W., Ko, B.-S., Wu, S., Huang, S., Hsu, S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253070 · Cited by 208
Wong, I. H. N., Ng, M. H. L., Huang, D. P., & Lee, J. C. K. (2000) · Blood · doi:10.1182/blood.v95.6.1942 · Cited by 199
Thol, F. R., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Göhring, G., Schumann, C., Bug, G., Ottmann, O. G., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 195
Self-citationSchambach, A., Wodrich, H., Hildinger, M., Bohne, J., Kräusslich, H.-G., & Baum, C. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0191 · Cited by 194
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Thol, F. R., Damm, F., Wagner, K., Göhring, G., Schlegelberger, B., Hoelzer, D. F., Lübbert, M., Heit, W. F. W., Kanz, L., Schlimok, G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272146 · Cited by 188
Self-citationHeuser, M., Argiropoulos, B., Kuchenbauer, F. C., Yung, E., Piper, J., Fung, S., Schlenk, R. F., Döhner, K., Hinrichsen, T., Rudolph, C., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080523 · Cited by 149
Self-citationStruys, E. A., Jansen, E. E. W., Verhoeven‐Duif, N. M., & Jakobs, C. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.033399 · Cited by 147
Self-citationMurugan, A. K., Bojdani, E., & Xing, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.095 · Cited by 135
Kölker, S., Pawlak, V., Ahlemeyer, B., Okun, J. G., Hörster, F., Mayatepek, E., Krieglstein, J., Hoffmann, G. F., & Köhr, G. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02055.x · Cited by 133
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 131
D‐2‐hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats
Latini, A., Scussiato, K., Rosa, R. B., Llesuy, S., Belló‐Klein, A., Dutra‐Filho, C. S., & Wajner, M. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02639.x · Cited by 112
Scherr, M., Chaturvedi, A., Battmer, K., Dallmann, I., Schultheis, B. S., Ganser, A., & Eder, M. (2005) · Blood · doi:10.1182/blood-2005-08-3087 · Cited by 111
Self-citationHeuser, M., Yap, D., Leung, M., de Algara, T. R., Tafech, A., McKinney, S. E., Dixon, J., Thresher, R. R., Colledge, B., Carlton, M. B. L., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162263 · Cited by 102
Self-citationHeuser, M., Yun, H., Berg, T., Yung, E., Argiropoulos, B., Kuchenbauer, F. C., Park, G., Hamwi, I., Palmqvist, L., Lai, C. K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.020 · Cited by 93
Self-citationHeuser, M., Sly, L. M., Argiropoulos, B., Kuchenbauer, F. C., Lai, C. K., Weng, A. P., Leung, M., Lin, G., Brookes, C., Fung, S., et al. (2009) · Blood · doi:10.1182/blood-2009-06-227603 · Cited by 80
Self-citationGurevich, R. M., Aplan, P. D., & Humphries, R. K. (2004) · Blood · doi:10.1182/blood-2003-10-3550 · Cited by 45
Functional role of BAALC in leukemogenesis
Heuser, M., Berg, T., Kuchenbauer, F. C., et al. (2011) · Leukemia · doi:10.1038/leu.2011.228 · Cited by 38
Self-citation
Research works printed but not linked: 1
- Irwin, ZINC: a free tool to discover chemistry for biology [published online ahead of print June 15, 2012]., J Chem Inf Model
Cited by
Sorted by citations
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.112 · Cited by 706
“For example, small molecule inhibitors of neomorphic IDH1 and IDH2 enzymes have shown initial promising results and induce differentiation of primary AML cells in vitro 158,159 .”
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626
“These mutations and proteins would suggest a model (Figure 7E) whereby mutant IDH1 may lead to high phosphoERK (Chaturvedi et al., 2013) and SRC can activate PI3K (Chen et al., 2015; Su et al., 2016), andwhere activatedmTOR signaling may activate transcription targets of hypoxia via HIF-1a…”
BackgroundIDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0814-x · Cited by 701
The Need for Multi-Omics Biomarker Signatures in Precision Medicine
Olivier, M., Asmis, R., Hawkins, G. A., Howard, T. D., & Cox, L. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194781 · Cited by 515
“The limited studies in cancer biology have identified some putative metabolic biomarkers, such as altered carbohydrates in acute myeloid leukemia [69], and unsaturated free fatty acids in colorectal cancer [70].”
BackgroundDifferentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Metadata
- Authors
- Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E. A., Jansen, E. E., Modlich, U., Li, Z., Sly, L. M., Geffers, R., Lindner, R., Manstein, D. J., Lehmann, U., Krauter, J., Ganser, A., & Heuser, M.
- Affiliations
- Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation,
- Institute of Experimental Hematology, and
- Medizinische Hochschule Hannover (DE)
- Vrije Universiteit Amsterdam (NL)
- University of British Columbia (CA)
- Helmholtz Centre for Infection Research (DE)
- Institute of Cell Biology (UA)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-17
- Volume
- 122
- Issue
- 16
- Pages
- 2877-2887
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2071370702
- Cited by
- 210
- References
- 45
- Citations by year
- 2026: 2 · 2025: 14 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 15 · 2020: 18 · 2019: 14 · 2018: 19 · 2017: 23 · 2016: 18 · 2015: 26 · 2014: 35 · 2013: 2
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, isocitrate dehydrogenase, acute myeloid leukemia, leukemogenesis, 2-hydroxyglutarate, HOXA9, myeloproliferative neoplasms, CDKN2A, CDKN2B, MAPK signaling, IDH1 inhibitor, therapeutic target
- MeSH terms
- Adolescent, Adult, Animals, Cell Cycle, Female, Humans, Isocitrate Dehydrogenase, Mice, Inbred C57BL, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Gene Expression Regulation, Leukemic, Bone Marrow Transplantation, Apoptosis, Antigens, CD34, MAP Kinase Signaling System, Mice, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
